MA33585B1 - Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée - Google Patents

Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Info

Publication number
MA33585B1
MA33585B1 MA34687A MA34687A MA33585B1 MA 33585 B1 MA33585 B1 MA 33585B1 MA 34687 A MA34687 A MA 34687A MA 34687 A MA34687 A MA 34687A MA 33585 B1 MA33585 B1 MA 33585B1
Authority
MA
Morocco
Prior art keywords
trifluoromethylphenyl
cyano
hydroxy
enoic acid
improved stability
Prior art date
Application number
MA34687A
Other languages
English (en)
Inventor
Gerrit Hauck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33585(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33585B1 publication Critical patent/MA33585B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES SOLIDES COMPRENANT DU (4'-TRIFLUOROMÉTHYLPHÉNYL)-AMIDE DE L'ACIDE (Z)-2-CYANO-3-HYDROXY-BUT-2-ÉNOÏQUE, AINSI QUE LEUR PROCÉDÉ DE PRÉPARATION, DES PROCÉDÉS D'UTILISATION DE TELLES COMPOSITIONS POUR TRAITER DES SUJETS SOUFFRANT DE MALADIES AUTO-IMMUNES, NOTAMMENT DE LUPUS ÉRYTHÉMATEUX SYSTÉMIQUE OU DE RÉACTIONS CHRONIQUES DE GREFFE CONTRE L'HÔTE, DE SCLÉROSE EN PLAQUES OU D'ARTHRITE RHUMATOÏDE.
MA34687A 2009-09-18 2012-03-13 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée MA33585B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18
US36338210P 2010-07-12 2010-07-12
PCT/EP2010/063439 WO2011032929A1 (fr) 2009-09-18 2010-09-14 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Publications (1)

Publication Number Publication Date
MA33585B1 true MA33585B1 (fr) 2012-09-01

Family

ID=41510564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34687A MA33585B1 (fr) 2009-09-18 2012-03-13 Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée

Country Status (40)

Country Link
US (5) US20120172427A1 (fr)
EP (1) EP2477611B1 (fr)
JP (1) JP2013505213A (fr)
KR (1) KR101547880B1 (fr)
CN (4) CN104739821B (fr)
AR (1) AR078383A1 (fr)
AU (2) AU2010297357B2 (fr)
BR (1) BR112012006184B1 (fr)
CA (1) CA2772275A1 (fr)
CL (1) CL2015000047A1 (fr)
CO (1) CO6511244A2 (fr)
CR (2) CR20170078A (fr)
CY (1) CY1119364T1 (fr)
DK (1) DK2477611T3 (fr)
DO (1) DOP2012000070A (fr)
ES (1) ES2625731T3 (fr)
GT (1) GT201200075A (fr)
HK (2) HK1206244A1 (fr)
HN (1) HN2012000576A (fr)
HR (1) HRP20170904T1 (fr)
HU (1) HUE032963T2 (fr)
IL (3) IL218492A (fr)
JO (1) JO3327B1 (fr)
LT (1) LT2477611T (fr)
MA (1) MA33585B1 (fr)
ME (1) ME02765B (fr)
MX (1) MX336663B (fr)
MY (1) MY155613A (fr)
NZ (2) NZ598744A (fr)
PE (2) PE20152031A1 (fr)
PL (1) PL2477611T3 (fr)
PT (1) PT2477611T (fr)
RS (1) RS56074B1 (fr)
RU (2) RU2012115459A (fr)
SI (1) SI2477611T1 (fr)
TN (1) TN2012000061A1 (fr)
TW (2) TWI468190B (fr)
UA (2) UA115979C2 (fr)
UY (1) UY32889A (fr)
WO (1) WO2011032929A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012115459A (ru) * 2009-09-18 2013-10-27 Санофи Таблетируюмый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
JP2016537360A (ja) * 2013-11-22 2016-12-01 ジェンザイム・コーポレーション 神経変性疾患を治療するための新規な方法
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
KR102479693B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 조합물
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (fr) * 2014-11-18 2016-05-26 Lupin Limited Composition pharmaceutique orale de tériflunomide
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016189406A1 (fr) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Composition pharmaceutique de tériflunomide
JP6917375B2 (ja) 2015-09-01 2021-08-11 ザ・ブロード・インスティテュート・インコーポレイテッド 血液がんの治療または予防に有用な化合物および方法
WO2017037645A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Formulations pharmaceutiques stables de tériflunomide
WO2017056104A1 (fr) * 2015-09-28 2017-04-06 Natco Pharma Limited Compositions pharmaceutiques stables de tériflunomide
WO2017125841A1 (fr) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Compositions pharmaceutiques de tériflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
AU2020315642A1 (en) * 2019-07-17 2022-03-03 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
WO2022085015A1 (fr) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited Composition orale solide de tériflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DK0787491T3 (da) 1994-10-17 2000-10-16 Aventis Pharma Ltd Middel til forebyggelse og behandling af allergiske sygdomme af type I
PT987256E (pt) 1997-08-08 2002-03-28 Aventis Pharma Gmbh Forma cristalina da n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2237553T3 (es) 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2005023185A2 (fr) * 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques et procede d'utilisation de la levodopa et de la carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
AU2005295511A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
JP2009524658A (ja) 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド レベチラセタム製剤、及びそれらの製造方法
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (fr) 2007-05-08 2009-05-06 Ulrike Wiebelitz Thérapie pour l'hyperplasie bénigne de la prostate
RU2012115459A (ru) * 2009-09-18 2013-10-27 Санофи Таблетируюмый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
EP2762135A1 (fr) * 2013-02-04 2014-08-06 Sanofi Procédés permettant de réduire le risque d'une interaction de la rosuvastatine et du tériflunomide indésirable chez des patients atteints de sclérose en plaques

Also Published As

Publication number Publication date
RU2015151938A (ru) 2019-01-15
HUE032963T2 (en) 2017-11-28
CN104666238A (zh) 2015-06-03
US20170247319A1 (en) 2017-08-31
CN104739821A (zh) 2015-07-01
KR20120089461A (ko) 2012-08-10
CN102596184A (zh) 2012-07-18
IL244809B (en) 2019-03-31
HRP20170904T1 (hr) 2017-09-08
PE20152031A1 (es) 2016-01-14
ES2625731T3 (es) 2017-07-20
CA2772275A1 (fr) 2011-03-24
PT2477611T (pt) 2017-06-05
CR20120116A (es) 2012-06-15
US20120208880A1 (en) 2012-08-16
HN2012000576A (es) 2015-01-26
NZ617025A (en) 2014-03-28
WO2011032929A1 (fr) 2011-03-24
US20140235888A1 (en) 2014-08-21
UA115979C2 (uk) 2018-01-25
AR078383A1 (es) 2011-11-02
GT201200075A (es) 2014-05-14
AU2013257516B2 (en) 2015-09-17
US20190241505A1 (en) 2019-08-08
IL218492A (en) 2016-04-21
IL218492A0 (en) 2012-04-30
RU2681079C2 (ru) 2019-03-04
CY1119364T1 (el) 2018-02-14
CN104666272A (zh) 2015-06-03
RU2012115459A (ru) 2013-10-27
JO3327B1 (ar) 2019-03-13
TWI522130B (zh) 2016-02-21
PL2477611T3 (pl) 2017-09-29
LT2477611T (lt) 2017-06-26
US20120172427A1 (en) 2012-07-05
BR112012006184B1 (pt) 2022-10-18
ME02765B (fr) 2018-01-20
RU2015151938A3 (fr) 2019-01-15
CO6511244A2 (es) 2012-08-31
HK1206244A1 (en) 2016-01-08
EP2477611B1 (fr) 2017-04-05
RS56074B1 (sr) 2017-10-31
TWI468190B (zh) 2015-01-11
MX336663B (es) 2016-01-27
CN102596184B (zh) 2015-03-11
TN2012000061A1 (en) 2013-09-19
TW201517935A (zh) 2015-05-16
JP2013505213A (ja) 2013-02-14
MY155613A (en) 2015-11-13
UA107582C2 (uk) 2015-01-26
PE20121478A1 (es) 2012-11-12
CN104739821B (zh) 2018-04-06
IL244809A0 (en) 2016-04-21
IL264912B (en) 2019-11-28
TW201117838A (en) 2011-06-01
EP2477611A1 (fr) 2012-07-25
US8802735B2 (en) 2014-08-12
DOP2012000070A (es) 2012-05-31
BR112012006184A2 (pt) 2016-05-31
KR101547880B1 (ko) 2015-08-27
HK1206245A1 (en) 2016-01-08
CN104666238B (zh) 2018-04-06
CR20170078A (es) 2017-05-22
SI2477611T1 (sl) 2017-07-31
CL2015000047A1 (es) 2015-06-12
MX2012003122A (es) 2012-04-10
AU2010297357A1 (en) 2012-04-05
DK2477611T3 (en) 2017-07-10
AU2010297357B2 (en) 2013-11-07
NZ598744A (en) 2013-11-29
UY32889A (es) 2011-04-29

Similar Documents

Publication Publication Date Title
MA33585B1 (fr) Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
WO2008064321A3 (fr) Procédés de traitement des maladies inflammatoires chroniques à l'aide d'un antagoniste du gm-csf
Behera et al. Hydrogen sulfide promotes bone homeostasis by balancing inflammatory cytokine signaling in CBS-deficient mice through an epigenetic mechanism
AU2011293135A8 (en) Pharmaceutical composition and administrations thereof
Archambault et al. Comparison of eight 15-lipoxygenase (LO) inhibitors on the biosynthesis of 15-LO metabolites by human neutrophils and eosinophils
JP2022521454A (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
WO2013185112A8 (fr) Compositions pharmaceutiques pour le traitement des troubles à médiation par cftr
MacFarlane et al. Shmt1 heterozygosity impairs folate-dependent thymidylate synthesis capacity and modifies risk of Apcmin-mediated intestinal cancer risk
Neubrand et al. Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TNSN07005A1 (fr) Analogues tetrapeptidiques
Benhammou et al. Novel lipid long intervening noncoding RNA, oligodendrocyte maturation‐associated long intergenic noncoding RNA, regulates the liver steatosis gene stearoyl‐coenzyme A desaturase as an enhancer RNA
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38925B1 (fr) Dérivés de phénylalanine substitués
Kwiecińska et al. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells
Qadir et al. Epigenetic modification related to acetylation of histone and methylation of DNA as a key player in immunological disorders
WO2010009377A3 (fr) Procédés et compositions pour une analyse pharmacogénétique de médicaments anti-inflammatoires dans le traitement d'une arthrite rhumatoïde et d'autres maladies inflammatoires
MX2007007610A (es) Regimen de cladribina para tratar esclerosis multiple.
Spugnini et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma